BidaskClub upgraded shares of Savara (NASDAQ:SVRA) from a sell rating to a hold rating in a research note released on Saturday.

SVRA has been the topic of several other research reports. Ladenburg Thalmann Financial Services began coverage on Savara in a research report on Wednesday, January 3rd. They set a buy rating and a $35.00 price objective on the stock. Zacks Investment Research cut Savara from a buy rating to a hold rating in a research report on Thursday, November 23rd. ValuEngine cut Savara from a sell rating to a strong sell rating in a research report on Friday, December 1st. Canaccord Genuity increased their price objective on Savara from $18.00 to $25.00 and gave the stock a buy rating in a research report on Monday, October 30th. Finally, Roth Capital lowered their price objective on Savara from $40.00 to $32.00 and set a buy rating on the stock in a research report on Tuesday, October 31st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company. Savara currently has an average rating of Buy and a consensus target price of $23.58.

Savara (NASDAQ SVRA) opened at $12.50 on Friday. The company has a current ratio of 9.15, a quick ratio of 9.15 and a debt-to-equity ratio of 0.20. The firm has a market capitalization of $356.86, a price-to-earnings ratio of -2.98 and a beta of -0.26. Savara has a 12-month low of $4.60 and a 12-month high of $17.19.

A number of hedge funds have recently bought and sold shares of the business. VHCP Management II LLC bought a new position in Savara during the 4th quarter worth $18,691,000. BlackRock Inc. increased its position in Savara by 642.4% during the 4th quarter. BlackRock Inc. now owns 499,512 shares of the company’s stock worth $7,412,000 after buying an additional 432,225 shares during the period. Sectoral Asset Management Inc acquired a new stake in shares of Savara during the 4th quarter worth $2,374,000. Geode Capital Management LLC grew its holdings in shares of Savara by 271.7% during the 4th quarter. Geode Capital Management LLC now owns 153,388 shares of the company’s stock worth $2,276,000 after purchasing an additional 112,118 shares in the last quarter. Finally, Brown Advisory Inc. acquired a new stake in shares of Savara during the 4th quarter worth $2,098,000. Hedge funds and other institutional investors own 18.43% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Savara (SVRA) Raised to Hold at BidaskClub” was originally published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this story can be viewed at https://theolympiareport.com/2018/02/14/savara-svra-raised-to-hold-at-bidaskclub.html.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

Analyst Recommendations for Savara (NASDAQ:SVRA)

Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.